A ctivated by IL-1 (interleukin 1) and oxidized LDL (low-density lipoprotein), 1 respectively, the IL-1R (IL-1 receptor) and the TLR4 (Toll-like receptor 4)-CD14 complex bind a group of signaling adaptors that include MyD88 (myeloid differentiation primary response gene 88) and members of the IRAK (IL-1R-associated kinase) family (IRAK1 and IRAK4).
A ctivated by IL-1 (interleukin 1) and oxidized LDL (low-density lipoprotein), 1 respectively, the IL-1R (IL-1 receptor) and the TLR4 (Toll-like receptor 4)-CD14 complex bind a group of signaling adaptors that include MyD88 (myeloid differentiation primary response gene 88) and members of the IRAK (IL-1R-associated kinase) family (IRAK1 and IRAK4). 2 IRAK triggers the oligomerization, activation, and auto-ubiquitination of the E3 ubiquitin ligase TRAF6 (TNFR [tumor necrosis factor receptor]-associated factor 6). The synthesis of K63-linked polyubiquitin chains by TRAF6 permits the scaffolding of signaling intermediates that include the TGFβ (transforming growth factor-β)-activated kinase 1, which activates IKKβ (IκB kinase β).
2 IKKβ phosphorylates IκBα (inhibitor of NF-κB), and thereby triggers K48-linked polyubiquitination, which tags IκBα for proteasomal degradation. 2 IκBα degradation promotes nuclear translocation of p65/p50 NFκB heterodimers, which mediate upregulation of proinflammatory target genes. 2, 3 IKKβ also phosphorylates the p65 subunit of NFκB on Ser536 and thereby activates its transcriptional activity. 4 In response to TNF, the TNFR1 also activates NFκB through cascades of polyubiquitination that culminate in the activation of IKKβ and phosphorylation of IκBα. 5 Activated TNFR1 promotes the association of a multiprotein complex that includes RIPK1 (receptor-interacting protein kinase 1), the ubiquitin E3 ligase and scaffolding protein TRAF2 (or TRAF5), and the ubiquitin E3 ligases cIAP1 (cellular inhibitor of apoptosis) or cIAP2. In this complex, autoubiquitinated cIAP1 (or cIAP2) ubiquitinates RIPK1 and provides a polyubiquitin platform for scaffolding of TGFβ-activated kinase 1, which can activate IKKβ. This polyubiquitin platform also associates with and activates the tripartite E3 ligase complex known as LUBAC (linear ubiquitin chain assembly complex). 6 LUBAC appends linear ubiquitin moieties to TNFR1, RIPK1, and IKKγ and can thereby promote IKKβ activation. 6 We previously demonstrated that the deubiquitinase called USP20 (ubiquitin-specific protease 20) inhibits TLR4-triggered NFκB activation by deubiquitinating TRAF6 in smooth muscle cells (SMCs). 7 Concordantly, SMC USP20 activity reduces neointimal hyperplasia induced by carotid endothelial denudation, as shown by transgenic mice expressing a dominant-negative (DN) USP20 mutant in SMCs. 7 Because SMC gene expression is known to affect atherogenesis, 8, 9 we used these SMC-specific transgenic mice to ask whether USP20 activity in SMCs affects atherosclerosis.
Materials and Methods
The authors declare that all supporting data are available within the article (and in the online-only Data Supplement).
Materials
Chemicals, reagents, and antibodies are listed in the online-only Data Supplement.
Mice
All animal experiments were performed in accordance with protocols approved by Duke University Institutional Animal Care and Use Committee. All mice were congenic on the C57BL/6 genetic background. Transgenic mice using the SM22 (transgelin) promoter for SMC-specific overexpression of USP20 (SMC-USP20) or its catalytically inactive mutant, dominant negative USP20 (SMC-DN-USP20) have been described. 7 These mice were crossed with Ldlr −/− mice to obtain the mice that were used for atherosclerosis studies. Verification of SMC-specific transgene expression was achieved with real time-polymerase chain reaction ( Figure I in the online-only Data Supplement).
Atherosclerosis Studies
These experiments adhered to the guidelines for experimental atherosclerosis studies described in the American Heart Association Statement. 9a Male mice from the age of 8 weeks were fed a Western diet for either 1 week (preatherosclerotic) or 16 weeks (atherosclerotic), as indicated, and then euthanized. Aorta and brachiocephalic artery preparation, staining, and quantitative assessment 10 are detailed in the online-only Data Supplement. All quantifications were performed by observers blinded to specimen identity.
Mouse Physiological Parameters
Serum total and high-density lipoprotein cholesterol were assayed as described. 10 Blood pressure and heart rate were measured as described.
10

Carotid Artery Interposition Grafting
This procedure was performed as we described.
11
Histology
Histochemical and immunofluorescence staining of tissue sections were performed on 5-μm sections and analyzed as we described. 7, 11 Quantification was performed by observers blinded to specimen identity as we described 7, 11 and as detailed in the online-only Data Supplement.
Cell Lines
Primary aortic SMCs were isolated from male and female mice as we reported. 10 Human embryo kidney (HEK-293) cells from the American Type Culture Collection were cultivated as reported. 7 HEK-293 cells with stable knockdown of USP20 were generated as described in the online-only Data Supplement.
RNA Interference
SMC transfection with siRNA (small interfering RNA) was performed as described 7 and as detailed in the online-only Data Supplement.
Adenovirus-Mediated Transduction
Recombinant adenoviruses expressing hemagglutinin-tagged USP20 constructs were generated with the AdEasy system (Agilent Technologies). Procedures are detailed in the online-only Data Supplement.
Immunoprecipitation and Immunoblotting
SMCs and HEK-293 cells were solubilized, and cellular proteins were immunoprecipitated as described 7 and as detailed in the onlineonly Data Supplement.
Polyubiquitinated Protein Pull-Down
Pull-down of polyubiquitinated proteins was performed using tandem ubiquitin binding entities (TUBEs 1, UM401) covalently linked to agarose beads, according to the manufacturer's protocol; details appear in the online-only Data Supplement.
USP20 Purification
USP20 was purified by immunoaffinity chromatography as we reported 12 and as detailed in the online-only Data Supplement. 
Deubiquitination of RIPK1 by Purified USP20
293-USP20 shRNA (short hairpin RNA) cells were transiently transfected with FLAG epitope-tagged human RIPK1 (pCDNA3/ FLAG-RIPK1, obtained from Addgene). 13 Twenty-four hours posttransfection, the cells were serum-starved for 4 hours and stimulated with 10 ng/mL TNF for 10 minutes. FLAG immunoprecipitation and deubiquitination reactions were performed as described in the onlineonly Data Supplement.
Statistical Analyses
All experiments were performed at least 3 independent times. Data from ≥3 independent experiments were averaged and presented as means±SEM. Statistical comparisons between 2 groups were made with t tests as noted in figure legends. Comparisons among >2 groups and analyses of time course data were made with 2-way ANOVA followed by the Sidak post hoc test for multiple comparisons, unless otherwise noted in the legend, using GraphPad Prism 7.03 statistics software (GraphPad, Inc). Statistical significance was set at P<0.05.
Results
SMC USP20 Activity Reduces Inflammation in Preatherosclerotic Aortas
To study the effects of SMC USP20 on atherogenesis, we used male Ldlr −/− mice with SMC-specific transgenic expression of either mouse USP20 (SMC-USP20) or the DN mutant of USP20 (SMC-DN-USP20). 7 Nontransgenic/Ldlr −/− , SMC-USP20-transgenic/Ldlr −/− , and SMC-DN-USP20-transgenic/Ldlr −/− mice (10-15 mice per group) were equivalent with regard to a variety of physical and metabolic parameters, including (1) body weight (32±2, 31±3, 31±3 g, respectively); (2) systolic blood pressure (124±6, 119±6, 122±4 mm Hg, respectively); (3) heart rate (680±30, 680±20, 670±20 bpm, respectively); and (4) serum total cholesterol concentration on a Western diet (23±5, 21±5, 23±5 mmol/L, respectively), serum high-density lipoprotein cholesterol concentration on a Western diet (1.0±0.3, 0.9±0.3, 0.9±0.4 mmol/L, respectively), and serum amyloid A concentration after just 1 week on a Western diet (32±6, 30±10, and 30±10 μg/mL, respectively).
In the initial stages of atherogenesis, endothelial cells and SMCs express on their plasma membranes adhesion molecules like VCAM-1 (vascular cell adhesion molecule-1), which facilitates the accumulation of monocyte/macrophages in the intima. 3 Expression of VCAM-1 is regulated by NFκB, 14 and USP20 regulates NFκB activation downstream of the atherogenic TLR4. 7 Accordingly, we asked whether altering SMC USP20 activity would alter the activation of NFκB or the expression of VCAM-1 in the aortas of atherogenic mice before the appearance of monocyte/ macrophages in the intima. To address this question, we used our SMC-USP20-transgenic/Ldlr −/− and SMC-DN-USP20-transgenic/Ldlr −/− mice. 7 USP20 expression was 2-or 3-fold greater than endogenous, respectively, in SMC-USP20-transgenic/Ldlr −/− and SMC-DN-USP20-transgenic/Ldlr −/− mice ( Figure 1A) . To accelerate atherogenesis, we fed these Ldlr −/− mice a Western diet 10 but harvested ascending aortas after only 7 days, at a time when intimal macrophages could not be detected ( Figure II in the online-only Data Supplement). 15 These preatherosclerotic aortas from nontransgenic/Ldlr −/− and 
SMC-USP20-transgenic/Ldlr
−/− mice showed equivalent activation of NFκB, assessed by immunofluorescence microscopy as phosphorylation of the NFκB subunit p65 on Ser536 7 in the tunica media, which comprises exclusively SMCs. Congruently, nontransgenic/Ldlr −/− and SMC-USP20-transgenic/Ldlr −/− mouse aortas also showed equivalent expression of VCAM-1. In contrast, the tunica media of preatherosclerotic aortas from SMC-DN-USP20-transgenic/Ldlr −/− mice demonstrated 40% to 50% higher levels of p65 Ser536 phosphorylation and VCAM-1 than nontransgenic/Ldlr −/− and SMC-USP20-transgenic/Ldlr −/− aortas ( Figure 1B and 1C) . Similarly, the level of IL-1β was 50% higher in the tunica media of preatherosclerotic aortas from SMC-DN-USP20-transgenic/Ldlr −/− mice ( Figure III in the online-only Data Supplement), even though SMC-DN-USP20-transgenic/Ldlr −/− and nontransgenic/Ldlr −/− preatherosclerotic aortas showed equivalent levels of MCP-1 (monocyte chemoattractant protein-1), TNF, and RIPK1 (an important effector downstream of the TNFR1). Thus, antagonizing USP20 activity in SMCs augmented inflammatory signaling in the earliest stages of atherogenesis.
SMC USP20 Attenuates Atherosclerosis
To determine whether USP20-dependent changes in SMC inflammation correlated with congruent effects on atherosclerosis, we studied nontransgenic/Ldlr accord with greater NFκB activation in DN-USP20-transgenic SMCs (Figure 1 ) and the role that NFκB plays in promoting SMC proliferation. 16 Although DN-USP20 augmented SMC signaling via NFκB in vitro and in vivo, it had no apparent effect on the SMC expression of HIF-1α (hypoxia-inducible factor-1α), which is a USP20 substrate in overexpression systems 17 ( Figure VI in the online-only Data Supplement). To corroborate our atherosclerosis findings in a parallel system, we transplanted carotid arteries from congenic nontransgenic (WT) and SMC-DN-USP20-transgenic mice into the carotid arteries of atherogenic Apoe −/− mice; the foam cellrich atherosclerosis that ensues mirrors results obtained by en face analysis of aortic atherosclerosis. 10, 11 Six weeks after transplantation, SMC-DN-USP20-transgenic arteries demonstrated 2.0±0.5-fold more atherosclerotic neointimal area and 2.0±0.6-fold less luminal area than nontransgenic control arteries ( Figure 
USP20 Reduces NFκB Activation In Vitro
At a cellular level, we previously found that lipopolysaccharide-induced NFκB activation was diminished in SMC-USP20-transgenic SMCs and augmented in SMC-DN-USP20-transgenic SMCs compared with nontransgenic SMCs. 7 To confirm these results in an independent system, we overexpressed USP20 or DN-USP20 in HEK-293T cells and assayed TNF-induced, NFκB promoter-driven luciferase activity ( Figure VIII in the online-only Data Supplement). TNF-induced NFκB activity was reduced by 40±8% in USP20-overexpressing cells. Conversely, it was increased by 40±4% in DN-USP20-overexpressing cells and by 50±7% in cells in which endogenous USP20 was silenced with siRNA ( Figure VIII in the online-only Data Supplement). Thus, our WT and DN-USP20 constructs exert reciprocal effects on TNF-induced NFκB activation, and DN-USP20 overexpression phenocopies the silencing of endogenous USP20.
USP20 Inhibits IL-1R-Evoked Inflammatory Signaling in SMCs
We have previously shown that USP20 inhibits both TLR4-mediated SMC inflammation in vitro and neointimal hyperplasia induced by carotid endothelial denudation in vivo. 7 Like TLR4, the IL-1R evokes canonical NFκB activation through MyD88 and the ubiquitin E3 ligase TRAF6. 18 Also like TLR4, 19 the IL-1R promotes atherosclerosis. 20 Therefore, we silenced USP20 expression in SMCs with siRNA to test whether USP20 attenuates NFκB activation in response to IL-1β; we used NFκB p65 phosphorylation on Ser536 as a read-out. 7 In response to IL-1β, p65 phosphorylation on Ser536 occurred more quickly and to a greater extent in USP20-silenced than in control-siRNA-treated SMCs designates NFκB [nuclear factor κB] p65 phosphorylated on Ser536). Immunoblots from single experiments are shown. B, Band densities for p-p65 were normalized to cognate β-actin bands. These ratios were normalized to that obtained in USP20-silenced SMCs stimulated with TNF (tumor necrosis factor) for 10 minutes, to obtain percent maximum, plotted as means±SE for 6 independent experiments. Compared with control-siRNA-transfected SMCs: *P<0.001. C, Data for IκBα (inhibitor of NF-κB) band densities were processed as in (B), except that the maximum IκBα/β-actin ratio for normalization was in control siRNA-transfected SMCs (6 independent experiments). Compared with control-siRNA-transfected SMCs: *P<0.01.
( Figure 3A and 3B) and in DN-USP20-expressing SMCs compared with control SMCs ( Figure IX in the online-only Data Supplement). Concordantly, IκBα degradation was faster in USP20-silenced than in control SMCs ( Figure 3A and 3C) . Thus, USP20 inhibits SMC inflammation in response to the atherogenic cytokine IL-1β, as it does in response to the atherogenic activation of TLR4.
7
USP20 Attenuates TNF-Induced Inflammatory Signaling in SMCs
Proinflammatory, proatherogenic signaling engaged by TNF emanates primarily from TNFR1, 11 which triggers canonical NFκB activation through ubiquitin E3 ligases distinct from TRAF6: TRAF2 or TRAF5, cIAP1 and cIAP2, and the ubiquitin ligase complex LUBAC. 21 The substrates for these E3 ligases are distinct from those of TRAF6. Therefore, we asked whether USP20 could regulate TNFR1-dependent NFκB activation in SMCs. To this end, we used both USP20-silencing siRNA and DN-USP20-transgenic SMCs. TNF-evoked p65 phosphorylation was 2-fold greater in USP20-silenced than in control SMCs and ≈2.7-fold greater in DN-USP20-transgenic than in nontransgenic SMCs (Figure 4A and 4B; Figure X in the online-only Data Supplement). Concordantly, IκBα degradation was ≈2-fold greater, and VCAM-1 upregulation was ≈3-fold greater in USP20-silenced than in control SMCs (Figure 4A and 4C; Figure XI in the online-only Data Supplement). Even in unstimulated SMCs, IκBα levels were ≈20% lower in USP20-silenced SMCs ( Figure 4A and 4C), as we observed previously, 7 consistent with a role for USP20 in constraining tonic canonical NFκB activation. Taken together, these data suggest that USP20 regulates TNF-induced NFκB activation in SMCs.
USP20 Associates With Proteins That Mediate TNF-Induced NFκB Activation
Although USP20 appears to inhibit TNFR1-dependent NFκB activation, the target or targets of USP20 deubiquitinase activity downstream of TNFR1 activation remain unknown. Indeed, the activated TNFR1 initiates dynamic ubiquitination of many proteins that collectively engender canonical NFκB activation. To identify potential substrates of USP20 and elucidate mechanisms by which USP20 inhibits TNF-evoked NFκB activity, we immunoprecipitated hemagglutinin-tagged USP20 from HEK-293 cells and immunoblotted for endogenous proteins that constitute TNFR1-activated signaling intermediates. With these coimmunoprecipitation assays, we found that USP20 associated with the ubiquitin E3 ligases TRAF2, cIAP1, and 2 components of LUBAC 6 : HOIP (heme-oxidized iron regulatory protein 2 ubiquitin ligase-1-interacting protein, or ring finger protein 31) and SHARPIN (SHANKassociated RH domain interacting protein; Figure XIIA in the online-only Data Supplement). In addition, USP20 associated with RIPK1, IκBα, and β-arrestin2 (Figure XIIB in the onlineonly Data Supplement). Of these USP20-associating proteins, only β-arrestin2 has previously been described. 7 In contrast, we could not detect specific association of USP20 with TNFR1, cIAP2, or IKKγ ( Figure XIIC in the online-only Data Supplement). Thus, USP20 can associate with at least a substantial subset of TNFR1-dependent signaling intermediates.
Having found that USP20 can associate with several TNFR1-activated signaling intermediates in HEK-293 cells, we next asked whether USP20 associates with any of these proteins Figure 3 . B, Immunoblot bands corresponding to NFκB (nuclear factor κB) p65 phosphorylated on Ser536 (phospho-p65 [p-p65]) were quantitated as in Figure 3 , for 3 independent experiments. Compared with control-siRNA-transfected SMCs: *P<0.05. C, Data for IκBα (inhibitor of NF-κB) were processed as in Figure 3 , for 3 independent experiments. Compared with control-siRNA-transfected SMCs: *P<0.01. TNFR1 indicates TNF receptor-1.
in SMCs and whether USP20 association was affected by TNF stimulation. To address these questions, we transduced primary WT SMCs with our hemagglutinin epitope-tagged-USP20-encoding adenovirus. USP20 immunoprecipitates demonstrated endogenous RIPK1 and SHARPIN on immunoblotting ( Figure XIIIA and XIIIC in the online-only Data Supplement), as well as TRAF2 and β-arrestin2 (data not shown). However, the association of USP20 with these proteins did not differ between unstimulated and TNF-stimulated SMCs ( Figure XIII in the online-only Data Supplement). Thus, it seems that USP20 constitutively associates with components of the TNFR1 signaling complex to regulate NFκB signaling and inflammation.
USP20 Deubiquitinates RIPK1
Among the TNFR1-activated, dynamically ubiquitinated proteins that associated with USP20 (Figures XII and XIII in the online-only Data Supplement), which ones are deubiquitinated by USP20? To address this question, we pulled down polyubiquitinated endogenous proteins from TNF-stimulated WT and DN-USP20-transgenic SMCs by using TUBEs. TUBEs are fusion proteins comprising 4 linearly arrayed ubiquitin-associated domains. 22 By immunoblotting SMC TUBEs pull-downs for RIPK1, we found that TNF engendered a 4-fold increase in RIPK1 ubiquitination ( Figure 5A and 5B). Importantly, this TNF-dependent RIPK1 ubiquitination was 2-fold greater in DN-USP20-transgenic SMCs than in nontransgenic SMCs-even though DN-USP20-transgenic and WT SMCs demonstrated equivalent levels of total ubiquitinated proteins in the TUBEs pull-downs ( Figure 5A and 5B). Immunoblotting TUBEs pull-downs for the LUBAC component SHARPIN yielded contrasting results: SHARPIN was constitutively ubiquitinated in SMCs, and there was no evidence of TNF-induced SHARPIN ubiquitination ( Figure 5C and 5D). Furthermore, SHARPIN ubiquitination was equivalent in WT and DN-USP20-transgenic SMCs ( Figure 5C and 5D). Taken together, these data suggest that whereas SHARPIN is not a substrate for USP20 in SMCs, RIPK1 is a USP20 substrate downstream of TNFR1 activation in SMCs.
Antagonizing USP20 activity in SMCs by low-level overexpression of DN-USP20 augmented TNF-induced RIPK1 ubiquitination ( Figure 5 ). However, it remained possible that USP20 reduced RIPK1 ubiquitination indirectly, rather than directly: for example, by deubiquitinating (and thereby deactivating) upstream E3 ubiquitin ligases and scaffolds like TRAF2 22a or HOIP, 23 with which USP20 associates in intact cells ( Figure XII in the online-only Data Supplement). To test whether USP20 directly deubiquitinates RIPK1 that has undergone TNF-induced ubiquitination in intact cells, we used purified USP20 to deubiquitinate RIPK1 immunoprecipitated from HEK-293 cells in which USP20 expression was reduced by RNAi (RNA interference; Figure 6A ). Our USP20 was >80% pure, as assessed by SDS-PAGE ( Figure 6B ). Purified UPS20 deubiquitinated RIPK1, as indicated by a 54±9% decrease in the ubiquitinated RIPK1 smear evident by immunoblotting RIPK1 immunoprecipitates for polyubiquitin ( Figure 6C and 6D) . Thus, RIPK1 itself appears to be a substrate of USP20, and by directly deubiquitinating RIPK1, USP20 can inhibit TNFR1-triggered NFκB signaling.
Discussion
This work demonstrates that the deubiquitinase USP20 impedes canonical NFκB activation by regulating ubiquitination-dependent signaling initiated by the IL-1R and the TNFR1 in SMCs. Furthermore, by impeding canonical NFκB activation in vivo, SMC USP20 activity attenuates atherosclerosis in Ldlr −/− mice. Assessed in intact cells or in preparations of purified proteins, USP20 deubiquitinates RIPK1 that signals downstream of TNFR1. These findings expand the previously known substrate specificity of USP20 beyond TRAF6 and HIF-1α, and expand the previously appreciated range of receptor signaling regulated by USP20. 17, [24] [25] [26] Specific roles in atherogenesis remain obscure for the ≈85 deubiquitinases in the mammalian proteome.
27 USP15 deubiquitinates IκBα in HeLa adenocarcinoma cells and in purified protein preparations 28 and thereby may inhibit NFκB activity as it seems to do in RAW 264.7 (transformed macrophagelike) cells 29 ; however, whether USP15 regulates NFκB activity in physiological systems remains an open question. USP31 can reduce NFκB activity when overexpressed in HEK-293 cells, but its physiological role and protein substrates remain obscure. 30 Although the ovarian tumor protease deubiquitinase subfamily member A20 can deubiquitinate TRAF6, diminish NFκB-dependent gene expression, and reduce atherosclerosis in Apoe −/− mice, 31 it seems that the deubiquitinase activity of A20 is not necessary for its ability to antagonize NFκB activity. 32 The USP-family deubiquitinase known as cylindromatosis protein can inhibit NFκB activation when it is overexpressed, 33 and RNAi-mediated silencing of cylindromatosis protein augments NFκB activity in HEK-293 cells. 34 However, at physiological levels of expression, cylindromatosis protein promotes aneurysm formation by deubiquitinating NOX4 (NADPH oxidase 4). 35 The deubiquitinase known as UCHL1 (ubiquitin C-terminal hydroxylase L1) attenuates TNF-induced NFκB activity assessed in A7r5 cells, but its substrates and physiological role remain enigmatic. 36 Because multiple loci in both canonical and noncanonical NFκB signaling pathways are regulated by ubiquitin-dependent mechanisms, it is not surprising that multiple deubiquitinases are involved in attenuating NFκB activity. 37 It remains to be seen whether USP20 coordinates with or complements substrate deubiquitination engendered by other deubiquitinases linked with NFκB signaling.
Atherogenesis is augmented by diverse signaling pathways that converge to activate IKKβ and thus NFκB. This general principle is illustrated by diminished atherosclerosis observed in mice lacking TNFR1,  11 cIAP2,  38 TLR4,  19 IL-1R,   39 MyD88, 19 IRAK4, 40 IKKγ, 41 or the NFκB p50 subunit in bone marrow cells. 42 However, although ablation of NFκB p50 in bone marrow cells reduces atherosclerosis, overexpressing NFκB p65 in macrophages also reduces atherosclerosis. 43 Furthermore, although ablating IKKβ reduces NFκB activation, ablating IKKβ in macrophages exacerbates atherosclerosis. 44 Similarly paradoxical data arise from investigations of TRAF6: endothelial cell TRAF6 ablation reduces atherosclerosis, but myeloid cell TRAF6 ablation augments atherosclerosis. 45 Therefore, it seems that the effects of NFκB activation on atherogenesis vary with both signaling inputs and cell type. 45, 46 Thus, the effects of deubiquitination on atherogenic signaling are likely to vary with the substrates of specific deubiquitinases. We have identified TRAF6, β-arrestin2, 7 and RIPK1 as substrates of USP20 in SMCs. Whether USP20 deubiquitinates other substrates in NFκB signaling cascades and whether USP20 activity affects TRAF6 and RIPK1 ubiquitination in a cell-specific manner remain to be determined.
RIPK1 rapidly associates with the TNF-activated TNFR1 signaling complex and undergoes polyubiquitination with multiple linkages.
5,47 RIPK1 K63 polyubiquitination is critical for scaffolding the TGFβ-activated kinase 1 complex that phosphorylates IKKβ. 47 Linear, methionine1-linked polyubiquitination of RIPK1 (effected by LUBAC) augments recruitment of IKKγ complexed to IKKα and IKKβ, which is then phosphorylated and thereby activated by TGFβ-activated kinase 1. 5 Thus, deubiquitination of RIPK1 diminishes downstream NFκB activation.
Deubiquitination of RIPK1 has been attributed to several deubiquitinases, in model cell lines and overexpression systems. In HEK-293T cells, the bifunctional A20 can remove K63-linked polyubiquitin from RIPK1 and also ubiquitinate RIPK1 with K48-linked polyubiquitin to promote proteasomal degradation of RIPK1 and consequent attenuation of NFκB activation. 48 Other deubiquitinases linked to RIPK1 in overexpression and other model systems include Cezanne, 49 USP2, 22a USP4, 50 and USP21. 51 Whether these deubiquitinases regulate RIPK1 in physiological systems or vascular cells remains to be explored. USP20 can deubiquitinate HIF-1α and thereby increase steady-state HIF-1α expression at least in overexpression systems. 17 However, we found that neither augmenting nor antagonizing SMC USP20 activity affected SMC HIF-1α expression in vivo, even though we found the expected 52 upregulation of HIF-1α in the context of atherogenesis ( Figure VI in the online-only Data Supplement). It may be that USP20 activity on HIF-1α requires levels of USP20 expression higher than those obtaining in SMCs or that SMCs lack the protein scaffold(s) required for USP20/HIF-1α interaction. Because HIF-1α activity in SMCs promotes atherosclerosis, 52 however, USP20-mediated deubiquitination of HIF-1α in SMCs would be expected to increase, rather than decrease, atherosclerosis.
Our data reveal that USP20 associates with additional mediators of TNFR-induced NFκB signaling, such as TRAF2, cIAP1, HOIP, IκBα, and β-arrestin2. It is thus possible that USP20 affects the dynamic ubiquitination of these signaling intermediates just as USP20 deubiquitinates RIPK1 (Figures 5 and 6 ) and β-arrestin2, 7 a multifunctional adaptor that regulates signaling downstream of both TNFR1 and TLR4. 7, 53 By deubiquitinating β-arrestin2, USP20 enables β-arrestin2 to scaffold a ternary complex of USP20, β-arrestin2, and TRAF6 and thereby facilitate . Protein extracts from these cells (20 μg) were serially immunoblotted for USP20 and β-actin. Shown is a single immunoblot (IB), representative of 3 performed. B, One μg of purified USP20 protein was resolved on 4% to 20% SDS-PAGE followed by Coomassie staining. USP20 (arrow) migrates with M r ≈110. C, 293-USP20 (Continued ) Figure 6 Continued. shRNA cells were transfected (or not, "-") with a plasmid encoding a FLAG epitope-tagged human RIPK construct. Cells were stimulated with TNF (10 ng/mL) for 10 minutes (37°C), solubilized, and then FLAG-RIPK1 was immunoprecipitated (IP). Immunoprecipitates were incubated at 37°C without ("-", control) or with ("+") 0.2 μg of purified USP20 for 1 hour, and then subjected to SDS-PAGE and IB. Nitrocellulose filters were probed sequentially for total polyubiquitin (Poly-Ub), RIPK1, and USP20, as indicated. Shown are results from a single experiment. D, The densities of polyubiquitin smears (Mr ≥64) were normalized to cognate RIPK1 band densities; these ratios were normalized to those obtained from incubations containing no deubiquitinase, to obtain % of control, plotted as means±SE of 3 experiments. Compared with control: *P<0.05 (1-sample t test).
deubiquitination of TRAF6 by USP20. 7 Perhaps because TLR4-promoted K63-linked polyubiquitination of β-arrestin2 abrogates its binding to USP20, 7 β-arrestin2 promotes neointimal hyperplasia, as well as atherosclerosis in Ldlr −/− mice. 54 Thus, the antiatherogenic effect of SMC USP20 may result from regulating β-arrestin2-mediated scaffolding, as well as from deubiquitinating other signaling intermediates downstream of TNFR1, IL-1R, and TLR4. For example, both β-arrestin2 53 and USP20 ( Figure XII in the online-only Data Supplement) associate with IκBα; therefore, it is possible that a ternary complex of USP20, β-arrestin2, and IκBα facilitates deubiquitination of IκBα-a possibility made more plausible by the observation that β-arrestin2 and its homolog β-arrestin1 can inhibit IκBα degradation and NFκB signaling downstream of TNFR1. 53 Our data demonstrate that USP20 plays an antiatherogenic role in SMCs. In so doing, our data add to the evidence demonstrating that SMC-specific gene expression affects atherosclerosis. 8, 9, 52 However, some limitations of our data merit further scrutiny. First, although antagonizing SMC USP20 increased NFκB activity in preatherosclerotic aortas, augmenting SMC USP20 activity failed to reduce NFκB activity (Figure 1 ). This apparent paradox may be attributable to the modest (≈2-fold) level of USP20 overexpression in SMC-USP20-transgenic/Ldlr −/− mice or to the short Western diet exposure (1 week) before harvesting the preatherosclerotic aortas. Plausibility of the latter hypothesis derives from our observation that SMC-USP20-transgenic/Ldlr −/− mice developed less aortic atherosclerosis than nontransgenic/Ldlr −/− control mice after an additional 15 weeks' exposure to Western diet. Second, there were relatively modest effects on atherosclerosis when we antagonized or augmented USP20 activity in SMCs. The magnitude of effects we observed was constrained by the modest levels of both WT USP20 and DN-USP20 transgene expression in mouse SMCs (≈2-and 3-fold, respectively). Furthermore, restriction of transgene expression to just SMCs likely further constrained the effects of USP20 transgenes on atherosclerosis. Our current data prompt the question of whether systemic or cell-type-specific ablation of USP20 will further demonstrate antiatherogenic efficacy of USP20 and thereby suggest therapeutic implications for augmenting USP20 activity. 
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